Drug Trial Radar · NCT07607964
A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions and Subcutaneous Injections of ABBV-519 in Adult Participants With Systemic Lupus Erythematosus (SLE) or Rheumatoid Arthritis (RA)
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
30
Planned (sponsor's estimate)
Start
May 28, 2026
Primary completion
Jan 2029
Study completion Jan 2029
Sponsor
- Lead sponsor
- AbbVieAbbVie (ABBV)
- Sponsor type
- Industry
- First posted
- May 27, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Basic science
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Systemic lupus erythematosus (SLE) is a chronic, systemic autoimmune disease characterized by B cell hyperactivity. Rheumatoid Arthritis (RA) is a chronic inflammatory disease causing pain, stiffness, swelling and loss of joint function. The purpose of this study is to assess the pharmacokinetics, pharmacodynamics and safety of ABBV-519 in adult participants with SLE or RA. This is a single ascending dose study in an estimated 30 adult participants with moderate SLE or RA. The total duration of the study will be approximately 425 days (60-day Screening Period, 1-day Treatment Period, and a 52 week Follow-up Period) at approximately 15 to 20 sites globally. There may be higher treatment burden for participants in this trial compared to their standard of care (due to study procedures). Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.
Conditions
- Systemic Lupus Erythematosus
- Rheumatoid Arthritis
Interventions
ABBV-519Drug
Intravenous (IV) Infusion
ABBV-519Drug
Subcutaneous (SC) Injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from Baseline in B Cells in BloodTime frame: Up to 365 Days
- Maximum Plasma Concentration (Cmax) of ABBV-519.Time frame: Up to 85 Days
- Time to Cmax (Tmax) of ABBV-519Time frame: Up to 85 Days
- Terminal Phase Elimination Half-Life (t1/2) of ABBV-519Time frame: Up to 85 Days
- Area Under the Concentration-Time Curve From Time 0 to Last Measurable Concentration (AUCt) of ABBV-519Time frame: Up to 85 Days
- Percentage of Participants with Detection of Anti-Drug Antibodies (ADAs) for ABBV-519Time frame: Up to 169 Days
- Number of Participants with Adverse Events (AEs)Time frame: Up to 425 Days
Locations
17 sites in 2 countries. Site status is shown where the registry gives one.
Pinnacle Research Group /ID# 278677
Anniston, Alabama · Recruiting
Solace Research /ID# 279155
Tustin, California · Recruiting
Clinical Research Of West Florida - Phase I Unit /ID# 279292
Clearwater, Florida · Recruiting
Finlay Medical Research - Greenacres /ID# 278380
Greenacres City, Florida · Recruiting
Clinical Research of Osceola /ID# 278374
Kissimmee, Florida · Recruiting
Allied Biomedical Research Institute /ID# 284408
Miami, Florida · Recruiting
Discovery Health Research Center /ID# 279691
Plantation, Florida · Recruiting
Clinical Research Of West Florida - Tampa - North Howard Avenue /ID# 279130
Tampa, Florida · Recruiting
Advanced Quality Medical Research /ID# 279147
Orland Park, Illinois · Recruiting
West Tennessee Research Institute - Jackson /ID# 284561
Jackson, Tennessee · Recruiting
Accurate Clinical Research - Houston /ID# 278382
Houston, Texas · Recruiting
Epic Medical Research /ID# 279180
Red Oak, Texas · Recruiting
Japan Community Healthcare Organization Chukyo Hospital /ID# 279611
Nagoya, Aichi-ken, Japan · Recruiting
Okayama University Hospital /ID# 279763
Okayama, Okayama-ken, Japan · Recruiting
Institute of Science Tokyo Hospital /ID# 279648
Bunkyo-ku, Tokyo, Japan · Recruiting
Keio University Hospital /ID# 280003
Shinjuku-ku, Tokyo, Japan · Recruiting
National Center for Global Health and Medicine /ID# 281191
Shinjuku-ku, Tokyo, Japan · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.